Reassuring evidence does not link AstraZeneca shot to blood clots, English medical official says
Reuters
Published Mar 17, 2021 01:39PM ET
LONDON (Reuters) - There is a lot of reassuring evidence that suggests there is no increased risk of blood clots from AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, England's deputy chief medical officer said, adding he expected the European Medicines Agency to agree.
"Behind the scenes, there is a lot of work going on to look at whether there is a signal in relation to what we call venous thrombo-embolic events - clots," Jonathan Van-Tam said at a news conference on Wednesday.
"And there's a lot of evidence emerging now that is reassuring that there is no overall excess signal or increased risk. And I expect, without prejudice to their absolute findings, those to be the final conclusions of the EMA and (Britain's) MHRA in due course."
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.